|
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission Clinical research trials and Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission. Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission clinical trial. Participants frequently get the best healthcare available for their Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission  Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
For Condition: Vitamin A Deficiency,HIV Seronegativity,HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: HIV infected individuals with vitamin A deficiency may be more likely to transmit the virus to others than HIV infected individuals who have normal levels of vitamin A. The presence of HIV DNA in vaginal secretions may indicate a greater risk for transmission of HIV to others. The purpose of this study is to determine if taking vitamin A decreases the level of HIV DNA in vaginal secretions.
Details: Vitamin A deficiency leads to pathological changes in mucosal epithelium, including the vagina, and is correlated with immune dysfunction in both HIV-1 infected and uninfected individuals. Recent studies of genital tract shedding of HIV-1 DNA in infected women have found that lower serum concentrations of vitamin A were strongly associated with detection of HIV-1 in vaginal secretions. In addition, maternal vitamin A deficiency has been associated with significantly increased risk of vertical HIV-1 transmission. This study will assess the effect of vitamin A supplementation on the prevalence and quantity of HIV-1 DNA and RNA in cervical and vaginal secretions. Participants in this study will be HIV infected nonpregnant women in Mombasa, Kenya. Participants will be randomized to receive 6 weeks of daily dosage of either 10,000 IU vitamin A or placebo. Cervical and vaginal swabs will be obtained at enrollment and at Week 6 for detection and quantification of HIV-1 DNA and RNA. In addition, venous blood will be obtained at the two time points for quantification of plasma HIV-1 RNA, CD4 lymphocyte count, and serum vitamin A levels.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: /
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - HIV infected Exlusion Criteria: - Pregnant
Total Enrollment: 400
Location and Contact Information:
Overall Study Official:
JoanKreiss, Principal Investigator, Universiy of Washington, Seattle, WA
Additional Information:
Study ID Numbers: R01-AI343844;
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00053612
Other Hiv Seronegativity Studies:
1. Atazanavir Used in Combination with Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
2. Using the Drug Thalidomide to Stimulate T Cells in HIV Positive Patients
3. A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
4. A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
5. A Study of MKC-442 in Combination with Other Anti-HIV Drugs
Related Studies:
Other HIV Seronegativity Clinical Trials
Other Clinical Trials
Other Clinical Trials
Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
|
|
|
|
|
|
|
|
